Variables associated with subclinical atherosclerosis among rheumatoid arthritis patients of Gulf Cooperative Council countries

Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease

Rheumatoid arthritis (RA), a chronic inflammatory autoimmune disorder, is characterised by persistent synovial inflammation, erosion of bones and cartilage, leading to joint destruction. Clinical manifestations are morning stiffness, pain in shoulder, neck and pelvic girdle, loss of mobility with fever, fatigue, malaise, loss of body weight, and development of rheumatoid nodules. Environmental and genetic factors are important contributors in its susceptibility. Association between RA and diet, cigarette smoking, hormones, alcohol, microbiota, infection, and coffee have also been reported. To diagnose patients with RA, American college of rheumatology (ACR, 2010) criteria, developed by European league against rheumatism (EULAR). Inflammation produced in RA patients is due to cell-mediated immune response. The rheumatoid synovium consists of a large number of CD4+ T cells suggesting pathogenic nature of T cells in this disorder. B-cells may also participate in the pathogenesis by several means such as autoantibodies, by instigation of T-cells through expression of co-stimulatory molecules, by generating pro-inflammatory and anti-inflammatory cytokines and by organisation of other inflammatory cells. The conventional management of RA usually focuses over reducing pain and limiting the disability by medical therapies which include a number of classes of agents such as non-steroidal anti-inflammatory drugs (NSAIDs), non-biological and biological agents, disease-modifying anti rheumatic drugs (DMARDs), immunosuppressants, and corticosteroids. However, only proper rehabilitation can promote the objective to achieve the joint functionality and ease of motion which improves independence as well as quality of life in patient suffering from Rheumatoid Arthritis.

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional risk factors such as smoking, arterial hypertension, dyslipidemia, insulin resistance, and obesity are frequently found in RA. Given the increased risk of mortality and morbidity associated with cardiovascular disease (CVD) in RA patients, screening for risk factors is important. Moreover, there is a need to identify potential predictors of subclinical atherosclerosis. Recent studies have shown that markers such as serum homocysteine, asymmetric dimethylarginine, or carotid intima-media thickness (cIMT) are correlated with cardiovascular risk. Although RA presents a cardiovascular risk comparable to that of diabetes, it is not managed as well in terms of acute cardiovascular events. The introduction of biological therapy has opened new perspectives in the understanding of this pathology, confirming the involvement and importance of the inflammatory markers, cytokines, and the immune system. In addition to effects in inducing remission and slowing disease progression, most biologics have demonstrated efficacy in reducing the risk of major cardiovascular events. Some studies have also been conducted in patients without RA, with similar results. However, early detection of atherosclerosis and the use of targeted therapies are the cornerstone for reducing cardiovascular risk in RA patients.

Evaluation of carotid artery elastic function using ultrafast pulse wave velocity in patients with rheumatoid arthritis

PURPOSE

Ultrafast pulse wave velocity (UFPWV) is an innovative and practical technology that can assess blood vessel elastic function. This study explored the elastic function of the carotid artery using UFPWV and factors influencing pulse wave velocity (PWV) in patients with rheumatoid arthritis (RA).

METHODS

Overall, 120 patients with RA and 60 healthy controls were evaluated. Participants underwent UFPWV and carotid artery intima-media thickness (cIMT) assessment. The patients were classified into a mild activity group (group A) and a moderate-to-severe activity group (group B). Differences in clinical indicators among the groups were determined, and the correlation between each indicator and PWV values was analyzed.

RESULTS

The PWV values were higher in group B than in group A and were higher in group A than in the control group (p < .05). The PWV values in the patient group positively correlated with anticyclic citrullinated peptide (anti-CCP) antibody, disease course, age, platelets (PLT) count, rheumatoid factor (RF), body mass index (BMI), total cholesterol (TC) level, and triglycerides (TG) level and were negatively correlated with 25-hydroxyvitamin D3 (25[OH]D3) and hemoglobin (Hb) levels (p < .05). In addition, anti-CCP antibody, age, RF, and low-density lipoprotein cholesterol were risk factors for arteriosclerosis, whereas Hb and 25(OH)D3 were protective factors (p < .05).

CONCLUSION

UFPWV allows early and accurate detection of changes in arterial elasticity and enables early intervention to reduce the incidence of cardiovascular events in patients with RA.

Ischemic Heart Disease and Rheumatoid Arthritis-Two Conditions, the Same Background

Rheumatoid arthritis (RA) is one of the most frequent inflammatory rheumatic diseases, having a considerably increased prevalence of mortality and morbidity due to cardiovascular disease (CVD). RA patients have an augmented risk for ischemic and non-ischemic heart disease. Increased cardiovascular (CV) risk is related to disease activity and chronic inflammation. Traditional risk factors and RA-related characteristics participate in vascular involvement, inducing subclinical changes in coronary microcirculation. RA is considered an independent risk factor for coronary artery disease (CAD). Endothelial dysfunction is a precocious marker of atherosclerosis (ATS). Pro-inflammatory cytokines (such as TNFα, IL-1, and IL-6) play an important role in synovial inflammation and ATS progression. Therefore, targeting inflammation is essential to controlling RA and preventing CVD. Present guidelines emphasize the importance of disease control, but studies show that RA- treatment has a different influence on CV risk. Based on the excessive risk for CV events in RA, permanent evaluation of CVD in these patients is critical. CVD risk calculators, designed for the general population, do not use RA-related predictive determinants; also, new scores that take into account RA-derived factors have restricted validity, with none of them encompassing imaging modalities or specific biomarkers involved in RA activity.

Subclinical atherosclerosis in rheumatoid arthritis patients of the Gulf Cooperated Council

OBJECTIVES

To assess the existence of subclinical atherosclerosis in the Gulf Cooperation Council (GCC) rheumatoid arthritis (RA) patients in comparison to age, gender and cardiovascular disease (CVD) risk factors matched controls. Methods: A cross-sectional study, 100 RA patients and 150 age, gender and CVD risk factors matched controls were recruited between June 2019 and December 2019. Detailed history, physical examination, and ultrasound examination of the carotid arteries for the carotid intima-media thickness (cIMT) and for the presence of atheroma, had been carried out. Differences between RA and controls carotid structural changes were carried out using t-test and Chi-test.

RESULTS

Patients with RA showed more sub-clinical atherosclerosis with thicker cIMT at 0.60±1.4 versus 0.56±0.09 mm, (p=0.03). cIMT is a surrogate marker for the presence of atherosclerosis and a predictor for the cardiovascular disease progression.  Rheumatoid arthritis patients had more carotid atherosclerotic plaque; 21 (21%) patients versus 6 (4%) healthy controls (p less than 0.001). Conclusion: Subclinical atherosclerosis is more prevalent among RA patients of the GCC than the control participants.

Comment on: Variables associated subclinical atherosclerosis among rheumatoid arthritis patients of Gulf Cooperative Council countries

[No Abstract Available].